The trial’s primary endpoint was achieved, establishing the maximum tolerated dose of SCO-101 in combination with the standard chemotherapies gemcitabine and nab-paclitaxel in patients with. | March 31, 2023
Scandion Oncology reports positive interim results from the CORIST Phase II study di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.
Scandion Oncology engages former ASCO executive as clinical advisor
Scandion Oncology is pleased to announce that we have appointed Dr. Richard L. Schilsky, a seasoned and highly profiled international leader as a member of our clinical advisory board (CAB). Dr. Schilsky is the former CMO and Executive Vice President of the American Society of Clinical Oncology (ASCO) and a long-time faculty member of the University of Chicago.
Scandion Oncology A/S
Publicerad: 21 april 2021, 11:30
Copenhagen, April 21, 2021. Scandion Oncology, The Cancer Drug Resistance Company, is pleased to announce that
Richard L. Schilsky, MD, FACP, FSCT, FASCO has accepted to join the clinical advisory board of Scandion Oncology.
Scandion Oncology appoints Dr Maj Hedtjärn as COO and Head of R&D Operations di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.